Teva Pharmaceutical Industries Ltd - Company Profile
Powered by 
All the data and insights you need on Teva Pharmaceutical Industries Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Teva Pharmaceutical Industries Ltd Strategy Report
- Understand Teva Pharmaceutical Industries Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Teva Pharmaceutical Industries Ltd (Teva), develops, manufactures, and sells generic and specialty medicines. The company offers medicines to treat disorders of the central nervous system (CNS), respiratory, dermatology, cancer, women's health, and other disease conditions. It also offers OTC products.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Teva’s R&D activities focuses on the development of novel medicines and biosimilar products for the treatment of disorders of the central nervous system, respiratory, cancer, women's health, dermatology and other disease conditions. Its pipeline includes a mix of novel and generic medicines, biosimilars and OTC medicines. As of December 31, 2023, the company owned 59 manufacturing and R&D facilities globally. In FY2023, the company spent US$953 million on R&D, which as a percentage of revenue stood at 6% and grew 14% YoY.
Geographical Segments
Overview
Provides generic, OTC, and specialty products. It licenses certain generic products to third parties. Its OTC portfolio includes brands such as SUDOCREM, NasenDuo, DICLOX, FORTE, OLFEN Max and FLEGAMINA. Specialty portfolio includes products for respiratory, oncology, and central nervous system (CNS).
Target Markets
Includes European Union, the UK, and other European countries.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Target Markets
Includes Japan, Russia, Israel, Latin America, Brazil, and Asia Pacific markets.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Markets generic prescription and OTC products in dosage strengths and several packaging sizes such as oral solid dosage forms, inhaled products, injectable products, liquids, ointments, and creams.
Target Markets
Includes the United States and Canada.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Includes the sale of APIs to third parties and contract manufacturing services. It offers a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer